DDDD 2014 - 7th Diabetes Drug Discovery and Development Conference

The International Diabetes Federation estimates that more than 285 million people world-wide have diabetes and 438 million people will have this disease within 20 years. Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of all diabetes and is characterized by insulin resistance combined with relatively reduced insulin secretion. The seven major markets for diabetes are expected to grow to 35 billion in 10 years driven by patient population expansion and novel therapies.
Come and join other diabetes experts at GTC’s 7th Diabetes Drug Discovery and Development Conference and hear key thought-leader's opinions to these questions and many more. This important meeting will be held on April 23-25, 2014 in Cambridge, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current and clinical drug development.
The Diabetes Drug Discovery and Development Conference includes the following sessions, panel discussions, and shared general sessions:
7th Diabetes Drug Discovery and Development:
Sessions:
I. New Therapeutic Targets for Diabetes
II. Combination Therapy
III. Clinical Drug Development in Diabetes
IV. Metabolic Syndrome Drug Development
V. Diabetic Complications
Panel Discussion:
I. Beyond HbA1c ? Are there Better Endpoints for Clinical Trials?
II. Med-Tech Advances for the Treatment of Diabetes
General Session I:
Joint session with the Diabetes Partnering & Deal-Making Conference
Topics:
I. Regulatory Landscape - Cardiovascular Safety
II. Biosimilar
III. Funding & Investments in Diabetes
IV. Health Economics
V. Type 1 Diabetes: "The New Honeymoon that Last Decades" - clinical trial opportunities and the new diverse type 1 diabetic population - can we more accurately predict complications?
General Session II:
Joint sessions with Diabetes Summit and 2014 Stem Cell Summit
Topics:
I. Cell Therapy and Diabetes - Stem Cell Research in the Diabetes Space
II. Cell Therapy Commercialization Model
III. Close Loop System
Panel Discussions:
I. Close Loop System vs Cell Therapy
II. Acquisitions in the Diabetes Regenerative Field and the Competitive Environment